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Which stroke patients gain most from intermittent pneumatic compression:
further analyses of the CLOTS 3 trial
Martin Dennis1*, Catriona Graham2, Joel Smith3, John Forbes4, and Peter Sandercock1 on
behalf of the CLOTS trial collaboration†
Background The CLOTS 3 trial showed that intermittent pneu-
matic compression (IPC) reduced the risk of DVT and improved
survival after stroke.
Aims To provide additional information which may help clini-
cians target IPC on the most appropriate patients by exploring
the variation in its effects on subgroups defined by predicted
prognosis.
Methods A multicentre, parallel group, randomized trial
enrolled immobile acute stroke patients and allocated them to
IPC or no IPC. The primary outcome was proximal DVT
at 30 days. Secondary outcomes at six-months included sur-
vival, disability, quality of life, and hospital costs. We stratified
patients into quintiles according to their predicted prognosis
at randomization, based on the Six Simple Variable model.
Results Between December 2008 and September 2012, we
enrolled 2876 patients in 94 UK hospitals. Patients with the
best predicted outcome had the lowest absolute risk of proxi-
mal DVT (6·7%) and death by six-months (9·3%). Allocation to
IPC had little effect on DVT, survival, disability, quality of life,
hospital length of stay, or costs. In patients with the worst
predicted outcomes, the overall risk of DVT and death was
16·0% and 51·3%, respectively. IPC reduced DVT (odds reduc-
tion 34%) and improved survival 17% and significantly
increased length of stay and hospital costs. In the three inter-
mediate quintiles, IPC reduced the odds of DVT (35–43%) and
improved survival (11–13%). Disability and quality of life at
six-months depended on baseline severity but was not influ-
enced significantly by IPC.
Conclusions IPC appears to reduce the risk of DVT and prob-
ably improves survival in all immobile stroke patients, other
than the fifth with the best prognosis. It therefore seems
reasonable to recommend that IPC should be considered in
all immobile stroke patients, but that the final decision
should be based on a judgment about the individual’s prog-
nosis. In some, their prognosis for survival with an accept-
able quality of life will be so poor that use of IPC might be
considered futile, while at the other end of the spectrum,
patients’ risk of DVT, and of dying from VTE, may not be
high enough to justify the modest cost and inconvenience of
IPC use.
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Introduction
Venous thromboembolism (VTE) is common after stroke, causes
significant morbidity, may delay hospital discharge, increases
healthcare costs, and has been estimated to account for up to a
quarter of all deaths after stroke (1). The CLOTS 3 trial showed
that intermittent pneumatic compression (IPC) applied to the
legs of immobile acute stroke patients reduces the odds of proxi-
mal DVT by about a third and improves survival over the first
six-months (hazard ratio = 0·86; 95%CI 0·73–0·99 P = 0·042) (2).
However, there were no significant differences between the treat-
ment and control groups in disability, living circumstances,
quality of life, or hospital costs (3). Based on these data, IPC has
been recommended in clinical guidelines (4) and is being widely
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implemented in stroke units throughout the United Kingdom (5).
However, those writing these guidelines questioned whether
IPC should be targeted on specific groups of immobile stroke
patients.
It has been suggested that trialists should report the heteroge-
neity of treatment effects in groups defined by more than one
characteristic as a way of providing decision makers with infor-
mation which might inform their decisions about which patients
are most likely to benefit from an intervention (6). We aimed to
establish whether there were categories of immobile stroke
patients, based on their predicted prognosis which takes account
of six variables at baseline, who may potentially gain more or less
from IPC, and in whom IPC might be more or less cost-effective.
Methods
The trial methods have been described in detail elsewhere
(2,3,7,8). In brief, the CLOTS 3 trial used a multicentre, parallel
group design with a centralized randomization system to allocate
treatment with a 1 : 1 ratio, and which ensured allocation con-
cealment. It enrolled consenting patients in 94 centers in the
United Kingdom, from Day 0 to 3 of admission, and allocated
them to IPC or no IPC on a background of routine care.
Between December 2008 and September 2012, we enrolled
2876 patients and completed follow-up in March 2013. Patients
were eligible for inclusion if they: were admitted to hospital
within three-days of an acute stroke (ischemic or hemorrhagic);
could be enrolled between the day of admission (day zero) and
day 3 in hospital; and were immobile (i.e. unable to walk inde-
pendently to the toilet). We excluded patients with subarachnoid
haemorrhage and those with severe peripheral vascular disease,
congestive heart failure, or skin lesions on the legs which are
considered to be contraindications to IPC.
Having obtained consent, the clinician entered the patient’s
baseline data into a computerized central randomization service
via a secure web interface. Once the computer program had
checked these baseline data for completeness and consistency, it
generated that patient’s treatment allocation – either ‘routine care
plus IPC’ or ‘routine care and no IPC’. A minimization algorithm
was used which included four variables: predicted stroke
outcome, delay from stroke onset to randomization, ability of the
patient to lift both legs off the bed, and use of anticoagulants or
alteplase. The patient’s probability of achieving a good outcome
[Oxford handicap scale (OHS) 0–2] was derived from the Six
Simple Variable (SSV) model which has been extensively tested
and validated in different cohorts (9,10). This includes the fol-
lowing variables:
• age
• prestroke independence in activities of daily living
• living alone at the time of the stroke
• ability to lift both arms off the bed
• ability to walk without help of another person (in this trial, no
patient could walk independently), and
• ability to talk and not to be confused (i.e. normal verbal com-
ponent of the Glasgow coma scale)
In patients allocated IPC, nursing staff applied the Kendall™
SCD express sequential compression system (Covidien, MA,
USA) with thigh-length sleeves to both legs, according to the
manufacturer’s instructions,. The sleeves were to be worn day and
night for 30 days or until: a second screening compression duplex
ultrasound (CDU) had been performed (if after 30 days); the
patient was independently mobile, discharged from the random-
izing hospital, refused to wear the sleeves, or the staff became
concerned about the patient’s skin.
The primary outcome was the occurrence of a symptomatic or
asymptomatic proximal DVT confirmed on CDU within 30 days
of randomization. Secondary outcomes included: survival to six-
months; disability (OHS (11)); quality of life (utilities based on
EQ5D-3L (12)); and hospital costs (based on cost of IPC and
length of hospital stay).
We estimated we would need 2800 patients to provide 90%
power (alpha 0·05) to identify a 4% absolute reduction in our
primary outcome (i.e. from 12% to 8%). For the purposes of all
analyses, we retained participants in the treatment group to which
they were originally assigned.We compared the proportions with
primary or secondary outcome events with odds ratios and 95%
confidence intervals (CIs). Survival was analyzed with a Cox
model, and the OHS at final follow-up was analyzed as an ordinal
scale by ordinal regression. All analyses were adjusted for the four
variables included in our minimization algorithm. The health-
related quality of life measured by the EQ5D–3L was converted
into a utility based on UK population preferences (13) on a range
of 1·0 (perfect health) to −0·5 (worst possible health). In this
setting, the range of utility values account for health states worse
than death.
The health economic methods have been described previously
(3). The costs took account of hospital length of stay as well as the
direct costs of IPC capital and equipment. Length of stay distri-
butions were converted into cost estimates based on a per-diem
hospital cost. Trial center/region-specific per-diem hospital costs
were based on NHS reference costs in England and cost informa-
tion for NHS Scotland derived from the Scottish Health Service
Costs resource (14,15). We only had data on survival to six-
months, so no reliable estimate of cost/QALY could be generated.
For these post hoc exploratory analyses, we divided the patients
into quintiles (Quintile 1 lowest probability/worst prognosis to 5
highest probability/best prognosis) based on their predicted
probability of having a good outcome at about six-months
derived from the baseline (prerandomization) measurement of
the SSV variables.
The protocol was approved by the Scotland A Multicentre
Research Ethics Committee (08/MREC00/73) & the Newcastle &
North Tyneside 1 Research Ethics Committee for England (08/
H0906/137). The study was jointly sponsored by University of
Edinburgh and NHS Lothian. The study is registered: http://
www.controlled-trials.com/ISRCTN93529999.
The funders of the study, including Covidien, had no role in
study design, data collection, storage, analysis or interpretation,
drafting of this report, or the decision to publish.All of the named
authors had full access to all data in the study and had final
responsibility to submit for publication.
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Results
The number of patients and the characteristics of the patients in
each quintile are shown in Table 1. The absolute risk and the effect
of IPC on the incidence of proximal DVTwithin 30 days (primary
outcome), deaths at six-months, survival to six-months, quality
adjusted survival, length of stay and hospital costs in each quin-
tile, and overall are shown in Table 2.While there is no statistically
significant heterogeneity across the groups, some patterns do
emerge. The risk of proximal DVT was similar across quintiles
1–4 but lower in the mildest quintile. With IPC, there is a similar
odds reduction in DVT (34– 43%) and absolute risk reduction
(4·6–5·8%) in all quintiles apart from quintile 5 (mildest) where
there was little evidence of an effect (7% and 0·5%, respectively).
The risk of dying by six-months was highest in quintile 5 (52%)
and gradually reduced across the quintiles to about 10%, confirm-
ing the predictive power of the SSV. Both the relative improve-
ment in survival (17%) and absolute reduction in death (7·3%)
with IPC was highest in quintile 1. However, there were smaller
improvements in survival in quintiles 4-2 (11–13%) but worse
survival (+40%) and higher absolute risk of death (2·1%) with
IPC in the mildest quintile. There was no statistically significant
gain in quality adjusted survival in the trial overall or any quintile.
Figure 1 illustrates that the functional outcomes of patients
improve as one moves from Quintile 1 (severest) to quintile 5
(mildest), confirming again the predictive value of the SSV. Using
an ordinal regression analysis adjusted for baseline variables,
there were no statistically significant treatment differences in the
distribution of OHS between those treated with IPC and the
untreated group, either overall or within any quintile. Overall,
the length of hospital stay was longer in the IPC group than the
control group, but this was most marked (6·8 days) and was
statistically significant in the severest quintile. Length of stay is the
main driver for hospital costs in the United Kingdom, which
explains the greater excess cost of hospital care associated with
allocation to IPC. This was largest and statistically significant in
severest quintile. The increased length of stay probably reflects the
improved survival.
Discussion
These further exploratory analyses suggest that patients in the
quintile with the highest probability of a good outcome may gain
little from IPC. Although IPC was associated with worse survival
in this group, it seem highly likely, given the wide CIs that this
observation was spurious. Furthermore, it appears that in patients
with the lowest probability of a good outcome, IPC has the largest
relative and absolute benefits on DVT and survival. The latter may
explain why IPC use is associated with a greater increase in length
of hospital stay and thus costs in the severest patients. The lack of
obvious benefits in the mildest group may arise because that
group have the lowest absolute risks of DVT and of dying within
six-months. It seems likely that deaths due to VTE, which are the
ones most likely to be reduced by IPC, will be uncommon in this
group.
There was a suggestion, based on the average effect of IPC
across all patient groups, that any improvement in survival may
be at the expense of patients surviving with severe disability
(3,16). These further, albeit post hoc and exploratory analyses,
provide some reassurance that while this may be true for the
severest patients, immobile stroke patients of intermediate
prognosis may still gain from IPC in terms of avoidance of DVT
and improved survival and with more acceptable functional out-
comes and probably less associated increase in overall hospital
costs.
These analyses show that the overall outcomes in both treat-
ment groups improve as one moves from the severest to mildest
quintile (Fig. 1), indicating that the SSV successfully stratifies
Table 1 Baseline characteristics of patients in each quintile defined by baseline prognosis derived from the Six Simple Variable (SSV) model
Quintile 1 (severest) 2 3 4 5 (mildest) All
Probability of OHS 0-2 at 6 months <0·01 0·01 to <0·046 0·046 to <0·13 0·13 to <0·396 0·396 to <1
Number per group 537 585 592 577 585 2876
Mean (SD) age 84·6 (7·3) 75·2 (10·1) 76·6 (9·1) 68·9 (12·7) 68·1 (12·4) 74·5 (12·1)
Male (%) 164 (30·5) 270 (46·2) 281 (47·5) 301 (52·2) 367 (62·7) 1383 (48·1)
Independent before 331 (61·6) 538 (92·0) 566 (95·6) 576 (99·8) 585 (100) 2596 (90·3)
Living alone 319 (59·4) 161 (27·5) 242 (40·9) 187 (32·4) 94 (16·1) 1003 (34·9)
Prior VTE 23 (4·3) 26 (4·4) 40 (6·8) 22 (3·8) 29 (5·0) 140 (4·9)
Diabetes mellitus 86 (16·0) 107 (18·3) 99 (16·7) 96 (16·6) 115 (19·7) 503 (17·5)
Current Smoker 42 (7·8) 83 (14·2) 89 (15·0) 139 (24·1) 125 (21·4) 478 (16·6)
Obese 124 (23·1) 171 (29·2) 176 (29·7) 186 (32·2) 217 (37·1) 874 (30·4)
Talking normally 52 (9·7) 110 (18·8) 441 (74·5) 543 (94·1) 585 (100) 1731 (60·2)
Lift both arms 49 (9·1) 60 (10·3) 142 (24·0) 200 (34·7) 550 (94·0) 1001 (34·8)
Lift both legs 86 (16·0) 88 (15·0) 180 (30·4) 207 (35·9) 426 (72·8) 987 (34·2)
Lift one leg 363 (67·6) 420 (71·8) 393 (66·4) 363 (62·9) 154 (26·3) 1693 (58·9)
Lift neither leg 88 (16·4) 77 (13·2) 19 (3·2) 7 (1·2) 5 (0·9) 196 (6·8)
Able to walk 0 0 0 0 0 0
Intra cerebral haemorrhage 64/535 (12·0) 82 (14·0) 82 (13·9) 82 (14·2) 66 (11·3) 376/2874 (13·2)
Use of blood thinning agents (heparin,
warfarin, thrombolysis)
100 (18·6) 152 (26·0) 123 (20·8) 164 (28·4) 160 (27·4) 699 (24·3)
The SSV variables are highlighted in grey.
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patients by predicted prognosis. In the severest group (quintile 1),
the great majority of patients are either dead or very severely
disabled. Nonetheless, even in this group, some patients may have
a good outcome, and in the mildest group (quintile 5), some
patients have poor outcomes. This may reflect not only a lack of
discrimination in the model but also some variability in the
scoring of the OHS by patients and carers, and the fact that some
patients, even with mild strokes, have poorer outcomes than
expected because they suffer recurrent strokes or develop other
severe co-morbidity.
The CLOTS 3 trial had some important limitations relevant to
these results. The trial was only powered to detect a 4% absolute
reduction in the risk of proximal DVT within 30 days, but it
lacked power to detect the improvements in survival, differences
in the OHS, quality of life or costs overall, and certainly not in five
subgroups. There was no statistically significant heterogeneity
between the quintiles in respect to the outcomes assessed, so that
any differences observed could have arisen due to the play of
chance. Even statistically significant effects of IPC in a quintile
may be spurious.
The lengths of stay and resulting costs of hospitalization are
based on UK practice where rehabilitation is often completed as
part of the initial acute hospital admission episode. In countries
where acute hospital stays for stroke are much shorter, IPC may
lead to greater use of rehabilitation facilities and/or community
care rather than acute hospital resources.
Awareness of these further analyses may increase clinicians’
confidence to select patients in whom IPC is likely to be both
effective and cost-effective. IPC appears to reduce the risk of DVT
and probably improves survival in all immobile stroke patients,
other than perhaps the fifth with the best prognosis. It therefore
seems reasonable to recommend that IPC should be considered in
all immobile stroke patients but that the final decision should be
based on a judgment about the individual’s prognosis. In some,
their prognosis for survival with an acceptable quality of life will
be poor. In these patients, discussion with the patient or family to
clarify the objectives of care may conclude that the use of IPC is
futile. At the milder end of the ‘severity’ spectrum patients’ risk of
DVT, and of dying from VTE, may not be high enough to justify
the modest cost and inconvenience of IPC use. These analyses
suggest that 60–80% of immobile stroke admissions will poten-
tially benefit from IPC.
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Fig. 1 The effect of IPC on disability (OHS) in each quintile. This shows the number and proportion of patients with an OHS of 0 (no symptoms), 1, 2,
3, 4, 5 (severe dependency), and 6 (dead) in each treatment group, in each quintile (quintile 1 severest – quintile 5 mildest). The patients with missing
OHS data – IPC 17 (1·2%) and no IPC 18 (1·3%) are excluded.
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